Ken Griffin Processa Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.18 - $0.84 $26,853 - $125,316
149,186 Added 89.75%
315,410 $107,000
Q3 2023

Nov 14, 2023
SELL
$0.24 - $0.53 $27,987 - $61,804
-116,613 Reduced 41.23%
166,224 $41,000
Q2 2023

Aug 14, 2023
BUY
$0.44 - $0.73 $124,448 - $206,471
282,837 New
282,837 $141,000

About Processa Pharmaceuticals, Inc.

PCSA Quotes by TradingView
  • Ticker PCSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,856,200
  • Market Cap $15.5M
  • Description
  • Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosi...
More about PCSA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email